Redx Pharma awarded grant to accelerate fibrosis project
The £515,595 grant was awarded to both Redx Pharma and Medicines Discovery Catapult who are leading the project.
The collaboration will enable a preclinical assessment, as well as informing a clinical development strategy for Redx’s Porcupine (RXC006) and ROCK2 inhibitors which aim to enter the clinic by 2021.
A multimodal approach will be undertaken by MDC to investigate novel biomarker signatures to characterise disease and treatment response.
The project, which is funded by Innovate UK, aims to accelerate the assessment of novel therapeutics for life-threatening fibrotic lung conditions which, amongst other fibrotic diseases, have a high unmet medical need.
Fibrotic diseases lack new therapies due to lack of translation between animal models and human disease -- additionally, robust biomarker strategies that can aid assessment in patients do not exist at present.
Redx’s project is working to validate and develop new biomarkers which are expected to assist a pipeline of new therapies for IPF, improving the likelihood of clinical success.
"This partnership with Redx will allow the development of a robust portfolio of biomarkers for IPF and the progression of anti-fibrotic therapies in a faster and better-informed way,” added Chief Scientific Officer of Medicines Discovery Catapult, Dr Peter Simpson.
Follow News & Updates from Nostra Terra here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.